|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2008-2-28
|
|
pubmed:abstractText |
Overexpression of B-cell lymphoma 2 (bcl-2) protein is a simple biological adverse prognostic factor that could delimit the poor prognosis population candidate for improvement with high-dose therapy and autologous stem-cell transplantation (ASCT) in diffuse large B-cell lymphoma (DLBCL). Therefore, we conducted a risk-adapted phase II study with ASCT as consolidation therapy in low-intermediate risk (LIR) International Prognostic Index patients aged < or = 60 years with bcl-2 overexpression (bcl-2+).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
pubmed-author:BrièreJJ,
pubmed-author:CopinM CMC,
pubmed-author:FermiGG,
pubmed-author:GaulardPP,
pubmed-author:GisselbrechtCC,
pubmed-author:Groupe d'Etude des Lymphomes de l'Adulte,
pubmed-author:HaiounCC,
pubmed-author:HermineOO,
pubmed-author:LederlinPP,
pubmed-author:MorelPP,
pubmed-author:MounierNN,
pubmed-author:SallesGG,
pubmed-author:TheateII,
pubmed-author:TillyHH
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
560-5
|
|
pubmed:meshHeading |
pubmed-meshheading:18096567-Adult,
pubmed-meshheading:18096567-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18096567-Bleomycin,
pubmed-meshheading:18096567-Cyclophosphamide,
pubmed-meshheading:18096567-Disease-Free Survival,
pubmed-meshheading:18096567-Doxorubicin,
pubmed-meshheading:18096567-Female,
pubmed-meshheading:18096567-Genes, bcl-2,
pubmed-meshheading:18096567-Humans,
pubmed-meshheading:18096567-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:18096567-Male,
pubmed-meshheading:18096567-Middle Aged,
pubmed-meshheading:18096567-Prednisone,
pubmed-meshheading:18096567-Prospective Studies,
pubmed-meshheading:18096567-Stem Cell Transplantation,
pubmed-meshheading:18096567-Survival Rate,
pubmed-meshheading:18096567-Transplantation, Autologous,
pubmed-meshheading:18096567-Vindesine
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2.
|
|
pubmed:affiliation |
Service d'Hématologie Clinique, Hôpital Schaffner, Lens, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
